Skip to Content
MilliporeSigma
  • Identifying Human PTP1B Enzyme Inhibitors from Marine Natural Products: Perspectives for Developing of Novel Insulin-Mimetic Drugs.

Identifying Human PTP1B Enzyme Inhibitors from Marine Natural Products: Perspectives for Developing of Novel Insulin-Mimetic Drugs.

Pharmaceuticals (Basel, Switzerland) (2022-03-27)
Marcello Casertano, Massimo Genovese, Lucia Piazza, Francesco Balestri, Antonella Del Corso, Alessio Vito, Paolo Paoli, Alice Santi, Concetta Imperatore, Marialuisa Menna
ABSTRACT

Diabetes mellitus (DM) represents a complex and multifactorial disease that causes metabolic disorders with acute and long-term serious complications. The onset of DM, with over 90% of cases of diabetes classified as type 2, implies several metabolic dysfunctions leading to consider DM a worldwide health problem. In this frame, protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AR) are two emerging targets involved in the development of type 2 diabetes mellitus (T2DM) and its chronic complications. Herein, we employed a marine-derived dual type inhibitor of these enzymes, phosphoeleganin, as chemical starting point to perform a fragment-based process in search for new inhibitors. Phosphoeleganin was both disassembled by its oxidative cleavage and used as model structure for the synthesis of a small library of functionalized derivatives as rationally designed analogues. Pharmacological screening supported by in silico docking analysis outlined the mechanism of action against PTP1B exerted by a phosphorylated fragment and a synthetic simplified analogue, which represent the most potent inhibitors in the library.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Insulin Receptor Antibody, beta subunit, clone CT-3, clone CT-3, from mouse